Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 1.00 |
| ▸ | F2 | P00734 | 18/20 | 1.00 |
| ▸ | CTRB1 | P17538 | 3/20 | 1.00 |
| ▸ | F9 | P00740 | 2/20 | 1.00 |
| ▸ | F5 | P12259 | 2/20 | 1.00 |
| ▸ | PROC | P04070 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Razaxaban SCHEMBL677372 | 1.00 | F10 (1.00) | F10F2CTRB1F9F5 | |
| Razaxaban SCHEMBL29456625 | 0.99 | F10 (1.00) | F10F2CTRB1F9F5 | |
| Razaxaban SCHEMBL6885838 | 0.99 | F10 (1.00) | F10F2CTRB1F9F5 | |
| SCHEMBL6493125 | 0.94 | F10 (0.88) | F10F2CTRB1F9F5 | |
| SCHEMBL5376245 | 0.92 | F10 (1.00) | F10F2CTRB1F9F5 | |
| SCHEMBL6503086 | 0.91 | F10 (1.00) | F10F2CTRB1F9F5 | |
| SCHEMBL6197266 | 0.91 | F10 (1.00) | F10F2CTRB1F9F5 | |
| SCHEMBL6198725 | 0.91 | F10 (1.00) | F10F2CTRB1F9F5 | |
| SCHEMBL5386162 | 0.91 | F10 (1.00) | F10F2CTRB1F9F5 | |
| SCHEMBL12589578 | 0.89 | F10 (1.00) | F10F2CTRB1F9F5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12521258-B2 | Anticoagulant compounds and methods and devices for their use | ELIXIR MEDICAL CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20250186563-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2025-06-12 | — | — | US | claimed |
| EP-3604510-B1 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2025-03-26 | — | — | EP | claimed |
| US-20250092380-A1 | ANTIDOTES TO FACTOR XA INHIBITORS | ALEXION PHARMA INC (US) | 2025-03-20 | — | — | US | claimed |
| US-20240424175-A1 | ANTICOAGULANT COMPOUNDS COMPRISING CHELATING AGENTS AND CATIONIC ANTI-COAGULATION ENHANCERS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2024-12-26 | — | — | US | claimed |
| WO-2024238703-A1 | ANTICOAGULANT COMPOSITIONS COMPRISING ANTI-PLATELET AND ANTI-INFLAMMATORY DRUGS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2024-11-21 | — | — | WO | claimed |
| WO-2024102699-A1 | GUANYLATE CYCLASE (GC) STIMULATOR FORMULATIONS AND USES THEREOF | ELANCO US, Inc. (US) | 2024-05-16 | — | — | WO | claimed |
| WO-2024095053-A1 | NOVEL NON-ORAL FORMULATIONS OF FACTOR XA INHIBITORS AND PROCESS FOR PREPARATION THEREOF | JODAS EXPOIM PVT. LTD (IN) | 2024-05-10 | — | — | WO | claimed |
| WO-2024072940-A1 | METHOD FOR MONITORING AND TREATING A DISORDER | NORTHWESTERN UNIVERSITY (US) | 2024-04-04 | — | — | WO | claimed |
| US-20240082367-A1 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2024-03-14 | — | — | US | claimed |
| US-20230293540-A1 | ANTICOAGULANT COMPOUNDS, METHODS AND DEVICES FOR OPHTHALMIC USE | ELIXIR MEDICAL CORPORATION (US) | 2023-09-21 | — | — | US | claimed |
| US-20230190499-A1 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2023-06-22 | — | — | US | claimed |
| WO-2023096800-A1 | ANTICOAGULANT COMPOUNDS COMPRISING CHELATING AGENTS AND CATIONIC ANTI-COAGULATION ENHANCERS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2023-06-01 | — | — | WO | claimed |
| US-11654036-B2 | Anticoagulant compounds and methods and devices for their use | ELIXIR MEDICAL CORPORATION (US) | 2023-05-23 | — | — | US | claimed |
| EP-4157383-A1 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR USE | Elixir Medical Corporation (US) | 2023-04-05 | — | — | EP | claimed |
| US-20230000957-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | PORTOLA PHARMACEUTICALS, LLC | 2023-01-05 | — | — | US | claimed |
| WO-2022056326-A1 | ANTICOAGULANT COMPOUNDS, METHODS AND DEVICES FOR OPHTHALMIC USE | ELIXIR MEDICAL CORPORATION (US) | 2022-03-17 | — | — | WO | claimed |
| WO-2022031758-A1 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR PULMONARY USE | ELIXIR MEDICAL CORPORATION (US) | 2022-02-10 | — | — | WO | claimed |
| US-20220039976-A1 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2022-02-10 | — | — | US | claimed |
| CN-116829545-B | Substituted pyrazolylpiperidine carboxylic acids | 拜耳公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-3400908-B2 | ARTIFICIAL VALVE PROSTHESIS | COOK MEDICAL TECHNOLOGIES LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12595247-B2 | Substituted pyrazolo piperidine carboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 2026-04-07 | — | — | US | disclosed |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-03 | — | — | US | disclosed |
| US-12521258-B2 | Anticoagulant compounds and methods and devices for their use | ELIXIR MEDICAL CORPORATION (US) | 2026-01-13 | — | — | US | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| US-12503469-B2 | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate | ADVERIO PHARMA GMBH (DE) | 2025-12-23 | — | — | US | disclosed |
| EP-4663636-A2 | TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250361282-A1 | ATRIAL NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES | BAYER AKTIENGESELLSCHAFT (DE) | 2025-11-27 | — | — | US | disclosed |
| US-12427131-B2 | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-09-30 | — | — | US | disclosed |
| US-20250281480-A1 | PHARMACEUTICAL DRY POWDER INHALATION FORMULATION | BAYER AG (DE) | 2025-09-11 | — | — | US | disclosed |
| US-20250282748-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-09-11 | — | — | US | disclosed |
| EP-4396183-B1 | SUBSTITUTED S-ALANINATE DERIVATIVES | BAYER AG (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-28 | — | — | US | disclosed |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2025-08-26 | — | — | US | disclosed |
| US-12398387-B2 | Compositions and methods for preparing factor Xa and derivatives | ALEXION PHARMACEUTICALS, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250263381-A1 | PROCESS FOR PREPARING (5S)-{[2-(4-CARBOXYPHENYL)ETHYL] |2-(2-{|3-CHLORO-4'-(TRIFLUOROMETHYL)BIPHENYL-4- YL]METHOXY}PHENYL)ETHYL]AMINOL-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLIC ACID AND ITS CRYSTALLINE FORMS FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | BAYER AKTIENGESELLSCHAFT (DE) | 2025-08-21 | — | — | US | disclosed |
| US-12390508-B2 | Brain natriuretic peptide engrafted antibodies | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-08-19 | — | — | US | disclosed |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-14 | — | — | US | disclosed |
| US-12384843-B2 | Anti-semaphorin 3A antibodies | BAYER AKTIENGESELLSCHAFT (DE) | 2025-08-12 | — | — | US | disclosed |
| US-20250236654-A1 | C-TYPE NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES | BAYER AKTIENGESELLSCHAFT (DE) | 2025-07-24 | — | — | US | disclosed |
| EP-4588932-A2 | PREPARATION OF FACTOR XA DERIVATIVES | ALEXION PHARMACEUTICALS, INC. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230144-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-07-17 | — | — | US | disclosed |
| EP-4160213-B1 | METHOD, ANALYSIS SYSTEM, ANALYZER, AND COMPUTER PROGRAM FOR ANALYZING CAUSE OF PROLONGING COAGULATION TIME | UNIV NIIGATA (JP) | 2025-07-09 | — | — | EP | disclosed |
| EP-4180424-B1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-112236196-B | Atrial natriuretic peptide grafted antibodies | 拜耳公司 | 2025-06-24 | — | — | CN | disclosed |
| US-12331094-B2 | Atrial natriuretic peptide engrafted antibodies | BAYER AKTIENGESELLSCHAFT (DE) | 2025-06-17 | — | — | US | disclosed |
| US-20250186563-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2025-06-12 | — | — | US | disclosed |
| EP-3926044-B1 | PREPARATION OF FACTOR XA DERIVATIVES | ALEXION PHARMA INC (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250163399-A1 | LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE | ALEXION PHARMA INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250154175-A1 | DIAZABICYCLIC SUBSTITUTED IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF BREATHING DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-15 | — | — | US | disclosed |
| CN-119868537-A | C-type natriuretic peptide grafted antibody | 勃林格殷格翰国际有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119868539-A | Naolinatriuretic peptide grafted antibodies | 勃林格殷格翰国际有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20250129112-A1 | Novel Prodrugs Derived from Nicotinic Acid and Ribose | MITOPOWER, INC. | 2025-04-24 | — | — | US | disclosed |
| EP-4541887-A2 | COMPOSITIONS AND METHODS FOR PREPARING FACTOR XA AND DERIVATIVES | ALEXION PHARMACEUTICALS, INC. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025080430-A1 | TREATMENT OF INTRACRANIAL HEMORRHAGE | ALEXION PHARMACEUTICALS, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-4536205-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION IN WOMEN | Bayer Aktiengesellschaft (DE) | 2025-04-16 | — | — | EP | disclosed |
| CN-114585637-B | MASP-inhibitory compounds and uses thereof | 拜耳公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2025068514-A1 | SUBSTITUTED HETEROCYCLIC CARBOXAMINDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2025-04-03 | — | — | WO | disclosed |
| EP-4010379-B1 | COMPOSITIONS AND METHODS FOR PREPARING FACTOR XA AND DERIVATIVES | ALEXION PHARMA INC (US) | 2025-04-02 | — | — | EP | disclosed |
| EP-3604510-B1 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20250092380-A1 | ANTIDOTES TO FACTOR XA INHIBITORS | ALEXION PHARMA INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-20250090519-A1 | TREATMENT OF CARDIOPULMONARY DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-03-20 | — | — | US | disclosed |
| EP-3473213-B1 | MONOCUSPID PROSTHETIC VALVE HAVING A PARTIAL SINUS | COOK MEDICAL TECHNOLOGIES LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4522123-A1 | LIQUID ORAL FORMULATION OF APIXABAN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | SYRI Research Private Limited (IN) | 2025-03-19 | — | — | EP | disclosed |
| US-12227779-B2 | Modified DDAH polypeptides and their use to extracorporeally treat a patient's blood to reduce levels of ADMA | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-02-18 | — | — | US | disclosed |
| US-20250051303-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES FOR THE TREATMENT AND/OR PROPHYLAXIS OF THROMBOTIC OR THROMBOEMBOLIC DISORDERS AND/OR THROMBOTIC OR THROMBOEMBOLIC COMPLICATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-02-13 | — | — | US | disclosed |
| CN-115073470-B | Pyrrolopyrimidinone derivative, and preparation method and application thereof | 南京中瑞药业有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20250026737-A1 | SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS | BAYER AG (DE) | 2025-01-23 | — | — | US | disclosed |
| EP-3487856-B1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | BAYER AG (DE) | 2025-01-22 | — | — | EP | disclosed |
| US-12202805-B2 | Process for preparing (5S)-{[2-(4-carboxyphenyl)ethyl] |2-(2-{|3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]aminol-5,6,7,8-tetrahydroquinoline-2-carboxylic acid and its crystalline forms for use as pharmaceutically active compound | BAYER AKTIENGESELLSCHAFT (DE) | 2025-01-21 | — | — | US | disclosed |
| CN-112292182-B | C-type natriuretic peptide grafted antibody | 勃林格殷格翰国际有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-112236197-B | Naolinatriuretic peptide grafted antibodies | 勃林格殷格翰国际有限公司 | 2025-01-17 | — | — | CN | disclosed |
| US-12195448-B2 | Substituted pyrazolo piperidine carboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 2025-01-14 | — | — | US | disclosed |
| US-12195774-B2 | Antidotes to factor XA inhibitors | ALEXION PHARMACEUTICALS, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| CN-119258012-A | Method for preparing pharmaceutical dosage forms comprising TASK-1 and TASK-3 channel inhibitors and their use in the treatment of respiratory disorders | 拜耳公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20250002483-A1 | SUBSTITUTED S-ALANINATE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2025-01-02 | — | — | US | disclosed |
| US-12180227-B2 | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | BAYER AKTIENGESELLSCHAFT (DE) | 2024-12-31 | — | — | US | disclosed |
| US-12178827-B2 | Nicotinyl riboside compounds and their uses | MITOPOWER LLC (US) | 2024-12-31 | — | — | US | disclosed |
| CN-119192081-A | Synthesis method of 1,3, 5-pyrazole compound | 徐州工程学院 | 2024-12-27 | — | — | CN | disclosed |
| US-20240424175-A1 | ANTICOAGULANT COMPOUNDS COMPRISING CHELATING AGENTS AND CATIONIC ANTI-COAGULATION ENHANCERS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2024-12-26 | — | — | US | disclosed |
| US-12173068-B2 | Anti-sema3a antibodies and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2024-12-24 | — | — | US | disclosed |
| US-12168673-B2 | Prodrugs derived from nicotinic acid and ribose | MITOPOWER, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-12162838-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2024238703-A1 | ANTICOAGULANT COMPOSITIONS COMPRISING ANTI-PLATELET AND ANTI-INFLAMMATORY DRUGS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-4463158-A2 | NOVEL PRODRUGS DERIVED FROM NICOTINIC ACID AND RIBOSE | Mitopower, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-12138256-B2 | Treatment of cardiopulmonary disorders | BAYER AKTIENGESELLSCHAFT (DE) | 2024-11-12 | — | — | US | disclosed |
| US-20240368668-A1 | SUBSTRATES AND BIOMARKERS OF ADAMTS7 | THE BROAD INSTITUTE, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-4457215-A1 | PROCESS FOR PREPARING (5S)-{[2-(4-CARBOXYPHENYL)ETHYL] 2-(2-{ 3-CHLORO-4'-(TRIFLUOROMETHYL)BIPHENYL-4- YL]METHOXY}PHENYL)ETHYL]AMINOL-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLIC ACID AND ITS CRYSTALLINE FORMS FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | Bayer Aktiengesellschaft (DE) | 2024-11-06 | — | — | EP | disclosed |
| EP-4456896-A1 | TREATMENT OF CARDIOPULMONARY DISORDERS | Bayer Aktiengesellschaft (DE) | 2024-11-06 | — | — | EP | disclosed |
| EP-4456871-A1 | PHARMACEUTICAL DRY POWDER INHALATION FORMULATION | Bayer Aktiengesellschaft (DE) | 2024-11-06 | — | — | EP | disclosed |
| CN-115175681-B | Use of sGC activators for the treatment of ophthalmic diseases | 拜耳公司 | 2024-10-25 | — | — | CN | disclosed |
| US-12116346-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| CN-118765272-A | Process for the preparation of (5S) - { [2- (4-carboxyphenyl) ethyl ] [2- (2- { [ 3-chloro-4' - (trifluoromethyl) biphenyl-4-yl ] methoxy } phenyl) ethyl ] amino } -5,6,7, 8-tetrahydroquinoline-2-carboxylic acid and crystalline forms thereof for use as pharmaceutically active compounds | 拜耳股份公司 | 2024-10-11 | — | — | CN | disclosed |
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-24 | — | — | US | disclosed |
| US-12097242-B2 | Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-24 | — | — | US | disclosed |
| WO-2024175450-A1 | SUBSTITUTED S-ALANINATE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-29 | — | — | WO | disclosed |
| US-12064429-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2024-08-20 | — | — | US | disclosed |
| EP-4413996-A2 | NOVEL ANTIBODIES AGAINST FACTOR XI AND USES THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2024-08-14 | — | — | EP | disclosed |
| US-20240254222-A1 | Novel Anti-Sema3a Antibodies And Uses Thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-01 | — | — | US | disclosed |
| EP-4399324-A1 | SUBSTRATES AND BIOMARKERS OF ADAMTS7 | The Broad Institute, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-113194924-B | Method for preparing pharmaceutical dosage forms comprising TASK-1 and TASK-3 channel inhibitors and their use in the treatment of respiratory disorders | 拜耳公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4396183-A1 | SUBSTITUTED S-ALANINATE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2024-07-10 | — | — | EP | disclosed |
| CN-113307772-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-118184582-A | 4-Seleno-1-benzenesulfonyl pyrazole compound and electrochemical synthesis method and application thereof | 延安大学 | 2024-06-14 | — | — | CN | disclosed |
| EP-3525779-B1 | COMBINATION CONTAINING THE SGC STIMULATOR VERICUGUAT AND THE MINERALCORTICOID RECEPTOR ANTAGONIST FINERENONE | Bayer Pharma AG (DE) | 2024-06-05 | — | — | EP | disclosed |
| EP-4058448-B1 | HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER AG (DE) | 2024-05-29 | — | — | EP | disclosed |
| WO-2024102699-A1 | GUANYLATE CYCLASE (GC) STIMULATOR FORMULATIONS AND USES THEREOF | ELANCO US, Inc. (US) | 2024-05-16 | — | — | WO | disclosed |
| CN-115677586-B | Polysubstituted aminopyrazole compound and preparation method and application thereof | 湖北省生物农药工程研究中心 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024095053-A1 | NOVEL NON-ORAL FORMULATIONS OF FACTOR XA INHIBITORS AND PROCESS FOR PREPARATION THEREOF | JODAS EXPOIM PVT. LTD (IN) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097829-A1 | APTAMER-DIRECT INHIBITOR CONJUGATES AND METHODS OF USING THE SAME | DUKE UNIVERSITY (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-05-09 | — | — | US | disclosed |
| US-20240150295-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-05-09 | — | — | US | disclosed |
| EP-3146977-B1 | TFPI INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-08 | — | — | EP | disclosed |
| CN-117916236-A | Substituted S-alanine ester derivatives | 拜耳公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| EP-3638675-B1 | DIAZABICYCLIC SUBSTITUTED IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF BREATHING DISORDERS | BAYER AG (DE) | 2024-04-17 | — | — | EP | disclosed |
| US-20240116874-A1 | PROCESS FOR PREPARING (5S)-{[2-(4-CARBOXYPHENYL)ETHYL] |2-(2-{|3-CHLORO-4'-(TRIFLUOROMETHYL)BIPHENYL-4- YL]METHOXY}PHENYL)ETHYL]AMINOL-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLIC ACID AND ITS CRYSTALLINE FORMS FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-11 | — | — | US | disclosed |
| US-20240109864-A1 | SUBSTITUTED PYRAZOLYL PIPERIDINE CARBOXYLIC ACIDS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-04 | — | — | US | disclosed |
| US-20240101528-A1 | SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-28 | — | — | US | disclosed |
| EP-3455224-B1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| US-20240082367-A1 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2024-03-14 | — | — | US | disclosed |
| US-20240084283-A1 | MODIFIED DDAH POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY, IMPROVED PHARMACOLOGY AND THEIR USES | UNIV INDIANA TRUSTEES (US) | 2024-03-14 | — | — | US | disclosed |
| US-20240076642-A1 | PREPARATION OF FACTOR XA DERIVATIVES | ALEXION PHARMA INC (US) | 2024-03-07 | — | — | US | disclosed |
| CN-117645564-A | Fluoroalkyl substituted indole derivative and synthetic method and application thereof | 齐鲁工业大学(山东省科学院) | 2024-03-05 | — | — | CN | disclosed |
| US-RE49860-E1 | Process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and purification thereof for use as pharmaceutical active ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-03-05 | — | — | US | disclosed |
| US-11912692-B2 | Substituted S-alaninate derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2024-02-27 | — | — | US | disclosed |
| US-20240051935-A1 | SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-02-15 | — | — | US | disclosed |
| US-20240050459-A1 | Nicotinyl Riboside Compounds and Their Uses | MITOPOWER LLC | 2024-02-15 | — | — | US | disclosed |
| EP-4314047-A1 | ANTI-SEMA3A ANTIBODIES AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2024-02-07 | — | — | EP | disclosed |
| US-RE49826-E1 | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-02-06 | — | — | US | disclosed |
| US-20240010684-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2024-01-11 | — | — | US | disclosed |
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11845966-B2 | Preparation of factor Xa derivatives | ALEXION PHARMACEUTICALS, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| WO-2023237873-A1 | TARGETS FOR CANCER THERAPY | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023237577-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION IN WOMEN | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-14 | — | — | WO | disclosed |
| US-11839646-B2 | Antidotes for factor Xa inhibitors and methods of using the same | ALEXION PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230391761-A1 | SUBSTITUTED S-ALANINATE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-07 | — | — | US | disclosed |
| US-11833167-B2 | Nicotinyl riboside compounds and their uses | MITOPOWER LLC (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230384331-A1 | BLOOD CHARACTERISTICS EVALUATION APPARATUS, BLOOD CHARACTERISTICS EVALUATION METHOD, AND NON-TRANSITORY COMPUTER READABLE RECORDING MEDIUM | CANON MEDICAL SYSTEMS CORPORATION (JP) | 2023-11-30 | — | — | US | disclosed |
| WO-2023218482-A1 | LIQUID ORAL FORMULATION OF APIXABAN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | SYRI RESEARCH PRIVATE LIMITED (IN) | 2023-11-16 | — | — | WO | disclosed |
| US-20230346777-A1 | USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES | BAYER AG (DE) | 2023-11-02 | — | — | US | disclosed |
| US-11793855-B2 | TFPI inhibitors and methods of use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-24 | — | — | US | disclosed |
| EP-3826627-B1 | ORALLY ADMINISTERABLE PHARMACEUTICAL DOSAGE FORM WITH MODIFIED RELEASE | BAYER AG (DE) | 2023-10-18 | — | — | EP | disclosed |
| EP-4259140-A1 | THE USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES | Bayer Aktiengesellschaft (DE) | 2023-10-18 | — | — | EP | disclosed |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | AMBRX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230322726-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| CN-116829545-A | Substituted pyrazolylpiperidine carboxylic acids | 拜耳公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230293540-A1 | ANTICOAGULANT COMPOUNDS, METHODS AND DEVICES FOR OPHTHALMIC USE | ELIXIR MEDICAL CORPORATION (US) | 2023-09-21 | — | — | US | disclosed |
| EP-3580232-B1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-4240750-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-09-13 | — | — | EP | disclosed |
| US-20230279035-A1 | Novel Prodrugs Derived from Nicotinic Acid and Ribose | MITOPOWER, INC. | 2023-09-07 | — | — | US | disclosed |
| WO-2023168329-A2 | NOVEL PRODRUGS DERIVED FROM NICOTINIC ACID AND RIBOSE | MITOPOWER, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| EP-4233796-A2 | MONOCUSPID PROSTHETIC VALVE HAVING A PARTIAL SINUS | Cook Medical Technologies LLC (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-116655629-A | Method for preparing compound and purification thereof for use as active pharmaceutical ingredient | 拜耳医药股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116655630-A | Method for preparing compound and purification thereof for use as active pharmaceutical ingredient | 拜耳医药股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116655627-A | Method for preparing compound and purification thereof for use as active pharmaceutical ingredient | 拜耳医药股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230265072-A1 | SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-24 | — | — | US | disclosed |
| US-20230263827-A1 | EXPANDED MEMORY SUBSETS OF GAMMA DELTA T CELLS FOR IMMUNOTHERAPY | GUMRUKCU SERHAT (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | MITOPOWER LLC | 2023-08-17 | — | — | US | disclosed |
| US-11708332-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708333-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-3325013-B2 | STIMULATORS / ACTIVATORS OF SOLUBLE GUANYLAT CYCLASE IN COMBINATION WITH A NEP-INHIBITOR AND AN ANGIOTENSIN AII-ANTAGONIST AND THE USE THEREOF | Bayer Pharma AG (DE) | 2023-07-19 | — | — | EP | disclosed |
| EP-4208536-A1 | EXPANDED MEMORY SUBSETS OF GAMMA DELTA T CELLS FOR IMMUNOTHERAPY | Gumrukcu, Serhat (US) | 2023-07-12 | — | — | EP | disclosed |
| US-RE49575-E1 | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-l,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-07-11 | — | — | US | disclosed |
| WO-2023126436-A1 | PROCESS FOR PREPARING (5S)-{[2-(4-CARBOXYPHENYL)ETHYL] |2-(2-{|3-CHLORO-4'-(TRIFLUOROMETHYL)BIPHENYL-4- YL]METHOXY}PHENYL)ETHYL]AMINOL-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLIC ACID AND ITS CRYSTALLINE FORMS FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023126438-A1 | PHARMACEUTICAL DRY POWDER INHALATION FORMULATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023126437-A1 | TREATMENT OF CARDIOPULMONARY DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-06 | — | — | WO | disclosed |
| CN-114411178-B | Polysubstituted pyrazole compound and electrochemical synthesis method thereof | 南京工业大学 | 2023-06-30 | — | — | CN | disclosed |
| US-11685721-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684621-B2 | Combination containing sGC stimulators and mineralocorticoid receptor antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-20230190499-A1 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2023-06-22 | — | — | US | disclosed |
| CN-106795155-B | Method for preparing compound and purification thereof for use as active pharmaceutical ingredient | 拜耳医药股份有限公司 | 2023-06-16 | — | — | CN | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| WO-2023096800-A1 | ANTICOAGULANT COMPOUNDS COMPRISING CHELATING AGENTS AND CATIONIC ANTI-COAGULATION ENHANCERS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2023-06-01 | — | — | WO | disclosed |
| US-11654036-B2 | Anticoagulant compounds and methods and devices for their use | ELIXIR MEDICAL CORPORATION (US) | 2023-05-23 | — | — | US | disclosed |
| CN-116157164-A | Anticoagulant compounds and methods and devices for using same | 万能医药公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-4180424-A1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| US-11638654-B2 | Detachable and retrievable stents for therapeutic agent delivery | COOK MEDICAL TECHNOLOGIES LLC (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230115270-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| CN-115925611-A | Fluoroalkyl substituted indole derivative and synthesis method thereof | 齐鲁工业大学 | 2023-04-07 | — | — | CN | disclosed |
| EP-4157383-A1 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR USE | Elixir Medical Corporation (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-4160213-A1 | METHOD, ANALYSIS SYSTEM, ANALYZER, AND COMPUTER PROGRAM FOR ANALYZING CAUSE OF PROLONGING COAGULATION TIME | Niigata University (JP) | 2023-04-05 | — | — | EP | disclosed |
| US-20230100082-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-03-30 | — | — | US | disclosed |
| US-20230094305-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-03-30 | — | — | US | disclosed |
| US-20230098487-A1 | METHOD, ANALYSIS SYSTEM, ANALYZER, AND COMPUTER PROGRAM FOR ANALYZING CAUSE OF PROLONGING COAGULATION TIME | NIIGATA UNIVERSITY (JP) | 2023-03-30 | — | — | US | disclosed |
| WO-2023039519-A1 | SUBSTRATES AND BIOMARKERS OF ADAMTS7 | THE BROAD INSTITUTE, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| WO-2023031083-A1 | SUBSTITUTED S-ALANINATE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-09 | — | — | WO | disclosed |
| US-20230065629-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
| US-20230056538-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-02-23 | — | — | US | disclosed |
| CN-115677586-A | Polysubstituted amino pyrazole compound and preparation method and application thereof | 湖北省生物农药工程研究中心 | 2023-02-03 | — | — | CN | disclosed |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230024752-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230000957-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | PORTOLA PHARMACEUTICALS, LLC | 2023-01-05 | — | — | US | disclosed |
| US-20220409618-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | ADVERIO PHARMA GMBH (DE) | 2022-12-29 | — | — | US | disclosed |
| US-20220389096-A1 | NOVEL ANTI-SEMA3A ANTIBODIES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-08 | — | — | US | disclosed |
| WO-2022236176-A2 | FXA PROTEIN FOR TREATING AND/OR PREVENTING COVID-19 | CITY OF HOPE (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20220354792-A1 | LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE | PORTOLA PHARMACEUTICALS, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20220331402-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2022-10-20 | — | — | US | disclosed |
| US-11472803-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-18 | — | — | US | disclosed |
| US-20220324836-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
| US-20220324865-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-10-13 | — | — | US | disclosed |
| CN-115175681-A | Use of sGC activators for the treatment of ophthalmic diseases | 拜耳公司 | 2022-10-11 | — | — | CN | disclosed |
| WO-2022207554-A1 | ANTI-SEMA3A ANTIBODIES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-06 | — | — | WO | disclosed |
| US-20220306602-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES FOR THE TREATMENT AND/OR PROPHYLAXIS OF THROMBOTIC OR THROMBOEMBOLIC DISORDERS AND/OR THROMBOTIC OR THROMBOEMBOLIC COMPLICATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-29 | — | — | US | disclosed |
| EP-4058448-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2022-09-21 | — | — | EP | disclosed |
| EP-4058446-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2022-09-21 | — | — | EP | disclosed |
| CN-115073470-A | Pyrrolopyrimidinone derivative and preparation method and application thereof | 南京中瑞药业有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20220274958-A1 | SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-01 | — | — | US | disclosed |
| EP-3828173-B1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2022-08-31 | — | — | EP | disclosed |
| CN-114981257-A | Substituted pyrazolopiperidinecarboxylic acids | 拜耳公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-109030837-B | Method for determining blood sample, and blood sample analyzer | 希森美康株式会社 | 2022-08-19 | — | — | CN | disclosed |
| US-20220257720-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. | 2022-08-18 | — | — | US | disclosed |
| US-20220259228-A1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-18 | — | — | US | disclosed |
| US-20220257547-A1 | ORALLY ADMINISTRABLE MODIFIED-RELEASE PHARMACEUTICAL DOSAGE FORM | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-08-18 | — | — | US | disclosed |
| WO-2022172788-A1 | BLOOD CHARACTERISTIC EVALUATION DEVICE, BLOOD CHARACTERISTIC EVALUATION METHOD, AND PROGRAM | キヤノンメディカルシステムズ株式会社 | 2022-08-18 | — | — | WO | disclosed |
| US-20220251534-A1 | COMPOSITIONS AND METHODS FOR PREPARING FACTOR XA AND DERIVATIVES | ALEXION PHARMACEUTICALS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| US-20220241273-A1 | USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES | BAYER AG (DE) | 2022-08-04 | — | — | US | disclosed |
| US-20220241255-A1 | COMBINATION CONTAINING SGC ACTIVATORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-08-04 | — | — | US | disclosed |
| US-20220234996-A1 | Method for Producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic Acid and the Crystalline Form Thereof for Use as a Pharmaceutical Ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-07-28 | — | — | US | disclosed |
| US-20220211812-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2022-07-07 | — | — | US | disclosed |
| EP-4021905-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | Bayer Aktiengesellschaft (DE) | 2022-07-06 | — | — | EP | disclosed |
| US-11377417-B2 | Branched 3-phenylpropionic acid derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2022-07-05 | — | — | US | disclosed |
| US-20220204961-A1 | MODIFIED DDAH POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY, IMPROVED PHARMACOLOGY AND THEIR USES | UNIV INDIANA TRUSTEES (US) | 2022-06-30 | — | — | US | disclosed |
| EP-3609883-B1 | FLUORINE-SUBSTITUTED INDAZOLE COMPOUNDS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2022-06-29 | — | — | EP | disclosed |
| CN-108883160-B | Lyophilized formulations of factor XA antidotes | 博尔托拉制药公司 | 2022-06-28 | — | — | CN | disclosed |
| US-11364281-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-21 | — | — | US | disclosed |
| WO-2022122917-A1 | THE USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-06-16 | — | — | WO | disclosed |
| EP-4010379-A2 | COMPOSITIONS AND METHODS FOR PREPARING FACTOR XA AND DERIVATIVES | Alexion Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-4011904-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2022-06-15 | — | — | EP | disclosed |
| CN-114585637-A | MASP inhibiting compounds and uses thereof | 拜耳公司 | 2022-06-03 | — | — | CN | disclosed |
| US-11344519-B2 | Orally administrable modified-release pharmaceutical dosage form | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-31 | — | — | US | disclosed |
| US-11337973-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-24 | — | — | US | disclosed |
| EP-2150208-B2 | MONOCUSPID PROSTHETIC VALVE HAVING A PARTIAL SINUS | COOK MEDICAL TECHNOLOGIES LLC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-11331314-B2 | Amine substituted triazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-17 | — | — | US | disclosed |
| US-11332435-B2 | Method for producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4- chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid and the crystalline form thereof for use as a pharmaceutical ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-17 | — | — | US | disclosed |
| US-11331308-B2 | Combination containing sGC activators and mineralocorticoid receptor antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-17 | — | — | US | disclosed |
| WO-2022096394-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | WO | disclosed |
| US-20220144795-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | UNIV INDIANA TRUSTEES (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220144848-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | US | disclosed |
| CN-114411178-A | Polysubstituted pyrazole compound and electrochemical synthesis method thereof | 南京工业大学 | 2022-04-29 | — | — | CN | disclosed |
| US-20220125894-A1 | METHODS FOR TREATING INTRACRANIAL HEMORRHAGE AND ASSESSING EFFICACY | ALEXION PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| EP-3986420-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | Mitopower LLC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11311605-B2 | Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides | AMBRX, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11298367-B2 | Prodrugs of substituted triazole derivatives and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2022-04-12 | — | — | US | disclosed |
| US-11286274-B2 | Nicotinamide riboside derivatives and their uses | MITOPOWER LLC (US) | 2022-03-29 | — | — | US | disclosed |
| US-20220089777-A1 | NOVEL HUMANIZED ANTIBODIES AGAINST FACTOR XI HAVING ANTI-THROMBOTIC AND ANTI-INFLAMMATORY EFFECT AND USES THEREOF | ARONORA INC (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220089591-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2022-03-24 | — | — | US | disclosed |
| WO-2022056326-A1 | ANTICOAGULANT COMPOUNDS, METHODS AND DEVICES FOR OPHTHALMIC USE | ELIXIR MEDICAL CORPORATION (US) | 2022-03-17 | — | — | WO | disclosed |
| EP-3966226-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2022-03-16 | — | — | EP | disclosed |
| WO-2022051520-A1 | EXPANDED MEMORY SUBSETS OF GAMMA DELTA T CELLS FOR IMMUNOTHERAPY | GUMRUKCU SERHAT (US) | 2022-03-10 | — | — | WO | disclosed |
| US-20220073515-A1 | FORMS OF METHYL {4,6-DIAMINO-2-[1 (2-FLUOROBENZYL)-1H-PYRAZOLO[3-4-B]PYRIDINO-3-YL]PYRIMIDINO-5-YL}METHYL CARBAMATE | ADVERIO PHARMA GMBH (DE) | 2022-03-10 | — | — | US | disclosed |
| US-11267780-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2022-03-08 | — | — | US | disclosed |
| US-20220062314-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | MitoPower, LLC (US) | 2022-03-03 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| WO-2022031758-A1 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR PULMONARY USE | ELIXIR MEDICAL CORPORATION (US) | 2022-02-10 | — | — | WO | disclosed |
| US-20220039976-A1 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2022-02-10 | — | — | US | disclosed |
| US-11242335-B2 | Fluorine-substituted indazole compounds and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-02-08 | — | — | US | disclosed |
| US-20220023246-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-01-27 | — | — | US | disclosed |
| US-20220023246-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | F10 992/4885F2 447/4885CTRB1 441/4885 |
| US-20220306602-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES FOR THE TREATMENT AND/OR PROPHYLAXIS OF THROMBOTIC OR THROMBOEMBOLIC DISORDERS AND/OR THROMBOTIC OR THROMBOEMBOLIC COMPLICATIONS | SELP, PNPO, SERPINC1 | F10 484/4885F2 10/4885CTRB1 2167/4885 |
| US-20240050459-A1 | Nicotinyl Riboside Compounds and Their Uses | NADK, NNT, NAMPT | F10 3756/4885F2 4207/4885CTRB1 3461/4885 |
| US-20220259228-A1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | HYOU1, DDAH1, VDAC3 | F10 4489/4885F2 4286/4885CTRB1 3316/4885 |
| US-20220062314-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | NADK, NNT, NAMPT | F10 3756/4885F2 4207/4885CTRB1 3461/4885 |
| US-20220324836-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | F10 1802/4885F2 3231/4885CTRB1 3530/4885 |
| US-20220324865-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | QDPR, SIRT5, PDXK | F10 1050/4885F2 15/4885CTRB1 851/4885 |
| US-20250092380-A1 | ANTIDOTES TO FACTOR XA INHIBITORS | SERPINC1, F2, F8 | F10 6/4885F2 2/4885CTRB1 131/4885 |
| US-11286274-B2 | Nicotinamide riboside derivatives and their uses | NME4, NADK, NQO1 | F10 4010/4885F2 4123/4885CTRB1 3597/4885 |
| US-11337973-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitors | PREP, PEPD, SERPINB1 | F10 1367/4885F2 398/4885CTRB1 100/4885 |
| US-20220234996-A1 | Method for Producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic Acid and the Crystalline Form Thereof for Use as a Pharmaceutical Ingredient | FABP3, PCCA, HMGCR | F10 1593/4885F2 682/4885CTRB1 173/4885 |
| US-20250230144-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | F10 1802/4885F2 3231/4885CTRB1 3530/4885 |
| US-20250129112-A1 | Novel Prodrugs Derived from Nicotinic Acid and Ribose | NME4, NADK, NNT | F10 3872/4885F2 2897/4885CTRB1 2369/4885 |
| US-20230265072-A1 | SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS | PLOD3, PDK4, PDF | F10 1349/4885F2 610/4885CTRB1 4240/4885 |
| US-20230100082-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | F10 115/4885F2 24/4885CTRB1 82/4885 |
| US-20250051303-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES FOR THE TREATMENT AND/OR PROPHYLAXIS OF THROMBOTIC OR THROMBOEMBOLIC DISORDERS AND/OR THROMBOTIC OR THROMBOEMBOLIC COMPLICATIONS | SELP, PNPO, SERPINC1 | F10 455/4885F2 6/4885CTRB1 2152/4885 |
| US-12064429-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | F10 2527/4885F2 1073/4885CTRB1 1109/4885 |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | F10 427/4885F2 850/4885CTRB1 182/4885 |
| US-20220073515-A1 | FORMS OF METHYL {4,6-DIAMINO-2-[1 (2-FLUOROBENZYL)-1H-PYRAZOLO[3-4-B]PYRIDINO-3-YL]PYRIMIDINO-5-YL}METHYL CARBAMATE | KDM2B, KDM6B, KDM3B | F10 1594/4885F2 576/4885CTRB1 1763/4885 |
| US-20250186563-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | SERPINC1, F8, F9 | F10 6/4885F2 4/4885CTRB1 85/4885 |
| US-11331314-B2 | Amine substituted triazole derivatives and uses thereof | GLS, TNNI3, NAT1 | F10 3335/4885F2 2095/4885CTRB1 1995/4885 |
| US-20220241273-A1 | USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES | PRKG1, PGC, PRKG2 | F10 4160/4885F2 4815/4885CTRB1 4084/4885 |
| US-12503469-B2 | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate | KDM2B, KDM6B, KDM3B | F10 2248/4885F2 551/4885CTRB1 1856/4885 |
| US-20220354792-A1 | LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE | F8, F11, F7 | F10 4/4885F2 7/4885CTRB1 49/4885 |
| US-20220144848-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | MVD, VASP, SELP | F10 445/4885F2 15/4885CTRB1 2963/4885 |
| US-20250263381-A1 | PROCESS FOR PREPARING (5S)-{[2-(4-CARBOXYPHENYL)ETHYL] |2-(2-{|3-CHLORO-4'-(TRIFLUOROMETHYL)BIPHENYL-4- YL]METHOXY}PHENYL)ETHYL]AMINOL-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLIC ACID AND ITS CRYSTALLINE FORMS FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | CYP3A5, CA5B, CA5A | F10 728/4885F2 181/4885CTRB1 884/4885 |
| US-12227779-B2 | Modified DDAH polypeptides and their use to extracorporeally treat a patient's blood to reduce levels of ADMA | ADM2, DDAH1, NPPA | F10 454/4885F2 273/4885CTRB1 1824/4885 |
| US-20240051935-A1 | SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS | PLOD3, PDK4, PDF | F10 1349/4885F2 610/4885CTRB1 4240/4885 |
| US-11311605-B2 | Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides | RXFP1, RXFP2, RXFP3 | F10 1089/4885F2 958/4885CTRB1 2110/4885 |
| US-12116346-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | F10 112/4885F2 29/4885CTRB1 85/4885 |
| US-12180227-B2 | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | HIF1AN, QDPR, DHPS | F10 4283/4885F2 2577/4885CTRB1 2730/4885 |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | F10 112/4885F2 29/4885CTRB1 85/4885 |
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | NADK, NNT, NAMPT | F10 3443/4885F2 4030/4885CTRB1 3405/4885 |
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | F10 112/4885F2 29/4885CTRB1 85/4885 |
| US-11708332-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | F10 115/4885F2 24/4885CTRB1 82/4885 |
| US-20240116874-A1 | PROCESS FOR PREPARING (5S)-{[2-(4-CARBOXYPHENYL)ETHYL] |2-(2-{|3-CHLORO-4'-(TRIFLUOROMETHYL)BIPHENYL-4- YL]METHOXY}PHENYL)ETHYL]AMINOL-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLIC ACID AND ITS CRYSTALLINE FORMS FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | CA5A, CYP3A5, CA5B | F10 666/4885F2 181/4885CTRB1 1177/4885 |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAMTS1 | F10 752/4885F2 721/4885CTRB1 771/4885 |
| US-12195448-B2 | Substituted pyrazolo piperidine carboxylic acids | PLOD3, PDK4, PDF | F10 1349/4885F2 610/4885CTRB1 4240/4885 |
| US-20220089591-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | AADAC, GLS, NAT1 | F10 3625/4885F2 3795/4885CTRB1 1163/4885 |
| US-12138256-B2 | Treatment of cardiopulmonary disorders | TNNT2, CA5B, PAH | F10 3346/4885F2 657/4885CTRB1 215/4885 |
| US-11267780-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | ADM2, DDAH1, BHMT | F10 3311/4885F2 1291/4885CTRB1 789/4885 |
| US-20230279035-A1 | Novel Prodrugs Derived from Nicotinic Acid and Ribose | NME4, NADK, NAMPT | F10 3803/4885F2 2858/4885CTRB1 1940/4885 |
| US-20220331402-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | F10 1149/4885F2 539/4885CTRB1 824/4885 |
| US-11912692-B2 | Substituted S-alaninate derivatives | AAAS, ALAD, AASDHPPT | F10 272/4885F2 15/4885CTRB1 2839/4885 |
| US-11364281-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof | RXFP2, RXFP1, RXFP4 | F10 1137/4885F2 395/4885CTRB1 777/4885 |
| US-20240084283-A1 | MODIFIED DDAH POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY, IMPROVED PHARMACOLOGY AND THEIR USES | DDAH1, ADM2, NPPA | F10 1840/4885F2 1507/4885CTRB1 1738/4885 |
| US-20250002483-A1 | SUBSTITUTED S-ALANINATE DERIVATIVES | AAAS, ALAD, AASDHPPT | F10 272/4885F2 15/4885CTRB1 2839/4885 |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | ADRA2C, ADRB3, ADRB2 | F10 3834/4885F2 4547/4885CTRB1 1089/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | F10 427/4885F2 850/4885CTRB1 182/4885 |
| US-12195774-B2 | Antidotes to factor XA inhibitors | SERPINC1, F2, F8 | F10 6/4885F2 2/4885CTRB1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.